Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CCMNASDAQ:PMDNASDAQ:RNLXNASDAQ:TOI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCMConcord Medical Services$5.70+3.4%$6.84$3.80▼$10.90$24.74M-0.8316,197 shs1,634 shsPMDPsychemedics$2.67$2.52$1.50▼$3.25$16.31MN/A34,058 shs113,627 shsRNLXRenalytix$0.21$0.23$0.18▼$2.40$17.18M2.721.45 million shs934,496 shsTOIOncology Institute$2.20+7.3%$2.73$0.13▼$3.50$196.31M0.131.11 million shs2.17 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCMConcord Medical Services+3.50%-1.22%-17.44%+34.51%-39.68%PMDPsychemedics0.00%0.00%0.00%0.00%+10.33%RNLXRenalytix0.00%0.00%0.00%0.00%-10.35%TOIOncology Institute-6.39%-10.48%-36.14%+62.70%+345.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCMConcord Medical ServicesN/AN/AN/AN/AN/AN/AN/AN/APMDPsychemedicsN/AN/AN/AN/AN/AN/AN/AN/ARNLXRenalytixN/AN/AN/AN/AN/AN/AN/AN/ATOIOncology Institute1.8181 of 5 stars3.52.00.00.02.30.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCMConcord Medical Services 0.00N/AN/AN/APMDPsychemedics 0.00N/AN/AN/ARNLXRenalytix 3.00Buy$3.001,348.58% UpsideTOIOncology Institute 3.00Buy$7.00218.18% UpsideCurrent Analyst Ratings BreakdownLatest PMD, RNLX, CCM, and TOI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025TOIOncology InstituteBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCMConcord Medical Services$52.60M0.47N/AN/A$51.05 per share0.11PMDPsychemedics$19.68M0.83N/AN/A$0.84 per share3.18RNLXRenalytix$2.29M7.50N/AN/A($0.10) per share-2.07TOIOncology Institute$393.41M0.50N/AN/A$0.05 per share44.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCMConcord Medical Services-$42.23MN/A0.00∞N/AN/AN/AN/AN/APMDPsychemedics-$1.86M-$0.51N/A∞N/A-9.26%-32.32%-18.53%N/ARNLXRenalytix-$33.46M-$0.39N/A∞N/A-1,461.60%N/A-281.40%N/ATOIOncology Institute-$64.66M-$0.70N/A∞N/A-15.38%-445.02%-34.13%8/12/2025 (Estimated)Latest PMD, RNLX, CCM, and TOI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TOIOncology InstituteN/A-$0.18N/A-$0.21N/A$104.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCMConcord Medical ServicesN/AN/AN/AN/AN/APMDPsychemedicsN/AN/AN/AN/A1 YearsRNLXRenalytixN/AN/AN/AN/AN/ATOIOncology InstituteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCMConcord Medical Services1.670.460.45PMDPsychemedics0.011.821.82RNLXRenalytixN/A0.530.53TOIOncology Institute14.581.791.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCMConcord Medical ServicesN/APMDPsychemedics32.07%RNLXRenalytix9.92%TOIOncology Institute36.86%Insider OwnershipCompanyInsider OwnershipCCMConcord Medical Services46.50%PMDPsychemedics13.96%RNLXRenalytix18.30%TOIOncology Institute8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionablePMDPsychemedics1406.11 million5.26 millionNot OptionableRNLXRenalytix10082.96 million63.06 millionOptionableTOIOncology Institute66089.23 million81.65 millionNot OptionablePMD, RNLX, CCM, and TOI HeadlinesRecent News About These CompaniesThe Oncology Institute and SilverSummit Healthplan Partner to Provide Oncology Care to Over 80,000 Medicaid Members in NevadaJune 30 at 4:05 PM | globenewswire.comInvesting in Oncology Institute (NASDAQ:TOI) a year ago would have delivered you a 376% gainJune 29 at 6:12 PM | finance.yahoo.comOncology Institute (NASDAQ:TOI) versus NeueHealth (NYSE:NEUE) Head to Head AnalysisJune 27, 2025 | americanbankingnews.comA game-changer in cancer research? South Korean scientists reprogram tumour cells without chemotherapy or radiationJune 25, 2025 | msn.comTOI - The Oncology Institute Inc Sustainability - MorningstarJune 24, 2025 | morningstar.comMApprovals for oncology procedures rise under Ayushman Bharat Arogya Karnataka schemeJune 10, 2025 | timesofindia.indiatimes.comThe Oncology Institute, Inc. (NASDAQ:TOI) Director Sells $232,788.20 in StockJune 10, 2025 | insidertrades.comJane Street Group LLC Has $39,000 Holdings in The Oncology Institute, Inc. (NASDAQ:TOI)June 10, 2025 | marketbeat.comThe Oncology Institute, Inc. (NASDAQ:TOI) Director Sells $232,788.20 in StockJune 9, 2025 | marketbeat.comInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 673,676 Shares of StockJune 9, 2025 | marketbeat.comInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 1,976,137 Shares of StockJune 6, 2025 | insidertrades.comBrad Hively Sells 1,976,137 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) StockJune 5, 2025 | marketbeat.comThe Oncology Institute set to join the Russell 2000® and Russell 3000® IndexesJune 3, 2025 | globenewswire.comShort Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Increases By 26.4%June 3, 2025 | marketbeat.comInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 203,532 Shares of StockMay 23, 2025 | insidertrades.comOncology Institute First Quarter 2025 Earnings: US$0.25 loss per share (vs US$0.22 loss in 1Q 2024)May 16, 2025 | finance.yahoo.comOncology Institute Shares Rise After Higher 1Q RevenueMay 15, 2025 | marketwatch.comThe Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 GuidanceMay 15, 2025 | finanznachrichten.deTOI reaffirms 2025 guidance with $460M–$480M revenue target as capitation contracts fuel growthMay 15, 2025 | msn.comQ1 2025 Oncology Institute Inc Earnings CallMay 15, 2025 | finance.yahoo.comThe Oncology Institute, Inc. (TOI) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMD, RNLX, CCM, and TOI Company DescriptionsConcord Medical Services NYSE:CCM$5.70 +0.19 (+3.45%) Closing price 03:45 PM EasternExtended Trading$5.70 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.Psychemedics NASDAQ:PMDPsychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.Renalytix NASDAQ:RNLXRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Oncology Institute NASDAQ:TOI$2.20 +0.15 (+7.32%) Closing price 04:00 PM EasternExtended Trading$2.23 +0.03 (+1.18%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
